Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol

Key facts

Sponsor

Institute of Hematology & Blood Diseases Hospital, China

Principal Investigator

Xiaofan Zhu, MD

Institute of Hematology and Blood Diseases Hospital, CAMS & PUMC

Intervention

Blinatumomab(drug)

Enrollment

3000 enrolled

Eligibility

1-18 years · All sexes

Timeline

2025 – 2033

Study locations (27)

• Anhui Medical University Second Affiliated Hospital, Hefei, Anhui, China
• Anhui Provincial Children's Hospital, Hefei, Anhui, China
• Chongqing Medical University Affiliated Children's Hospital, Chongqing, Chongqing Municipality, China
• Fujian Medical University Union Hospital, Fuzhou, Fujian, China
• Guangzhou Women and Children's Medical Center, Guangzhou, Guangdong, China
• Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
• The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi, China
• The Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, China
• Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
• Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
• Wuhan Children's Hospital, Wuhan, Hubei, China
• Hunan Children's Hospital, Changsha, Hunan, China
• The Third Xiangya Hospital of the Central South University, Changsha, Hunan, China
• Xiangya Hospital Central South University, Changsha, Hunan, China
• Nanjing Children's Hospital Affiliated to Nanjing Medical University, Nanjing, Jiangsu, China
• +12 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Acute lymphoblastic leukemia

Additional recruiting or active studies for the same condition.

• RECRUITINGNANCT05621291
  A Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymphoblastic Leu...
  National Cancer Institute (NCI)
• ENROLLING BY INVITATIONNCT07511959
  Autologous Exosomes From Platelet-rich Plasma as a Modern Tool of Regenerative Dentistry
  Wroclaw Medical University
• RECRUITINGPHASE2NCT06738368
  Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia
  University of Washington
• RECRUITINGNANCT07191119
  Transcutaneous Auricular Vagus Nerve Stimulation for Insomnia in Survivors of Childhood Acute Lymphoblastic Leukemia
  St. Jude Children's Research Hospital
• RECRUITINGNANCT07177183
  Low Serum Creatinine as a Predictor of Prolonged Mechanical Ventilation and Weaning Failure
  University Hospital Ostrava
• RECRUITINGPHASE2NCT07275762
  Y-4 to Treat the Postherpetic Neuralgia
  Neurodawn Pharmaceutical Co., Ltd.
• ENROLLING BY INVITATIONNCT07515430
  The Association Between Gut Microbiome Composition Signature and Cancer-related Symptoms in Children With Acute Lymphoblastic Leukemia
  Sun Yat-sen University
• RECRUITINGNANCT07201974
  Virtual Reality for Post-Stroke Gait Rehabilitation
  McGill University

See all trials for Acute lymphoblastic leukemia →